UnverferthDVUnverferthBJBalcerzakSPBashoreTANeidhartJA. Cardiac evaluation of mitoxantrone. Cancer Treat Rep1983; 67:343–50.
2.
AaproMMackelCAlbertsDWoolfendenJ. Phase II cardiotoxicity study of mitoxantrone hydrochloride using exercise radionuclide evaluation of the left ventricular cardiac ejection fraction. Proc Am Soc Clin Oncol1982; 1: 14.
3.
SchellFCYapHYBlumenscheinGValdiviesoMBodeyG. Potential cardiotoxicity with mitoxantrone. Cancer Treat Rep1982; 66:1641–3.
4.
PrattCBCromDBWallenbergJ, Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin. Cancer Treat Rep1983; 67:85–8.
5.
SmithIE. Mitoxantrone (Novantrone): A review of experimental and early clinical studies. Cancer Treat Rev1983; 10:103–15.
6.
Stuart-HarrisRCBozekTPavlidisNASmithIE. Mitoxantrone: An active new agent in the treatment of advanced breast cancer. Cancer Chemother Pharmacol1984; 12:1–4.
7.
MalleyRGamsR. Phase II study of mitoxantrone in patients with metastatic breast carcinoma: A Southeastern Cancer Study Group project. Cancer Treat Rep1983; 67:1039–40.
8.
ColemanREMaiseyMNKnightRKRubensRD. Mitoxantrone in advanced breast cancer—a phase II study with special attention to cardiotoxicity. Eur J Cancer Clin Oncol1984; 20:771–6.
